An additional post hoc factor analysis revealed a significant efficacy of STW 5‐II associated with the meal‐related FD symptoms “early satiety” and “loss of appetite.” A clear trend in numerical, but non‐significantly reduction in GIS from baseline was observed in the STW 5‐II group compared with the placebo group at the end of the trial ( P = 0.072), demonstrating improvement of self‐reported symptoms and supporting the outcomes of the first endpoint.
← all excerpts
Double-blind, randomized, 8-week multicenter study of the efficacy and safety of STW 5-II<i>versus</i> placebo in functional dyspepsia.
1
—
—